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Introduction
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have played an important role in antiretroviral combination regimens for the treatment of the human immunodeficiency virus (HIV)-1 infection, along with nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, CCR5 antagonists, and integrase inhibitors (Klimas et al., 2008) . However, the first generation of NNRTIs suffers from a low genetic barrier to resistance (de Béthune, 2010; Thompson et al., 2010) . BILR 355 ( Fig. 1) is a "second generation" NNRTI which was developed for the treatment of HIV-1 infection in adults and children (Boone, 2006; Bonneau et al., 2005) . BILR 355 is highly specific toward HIV-1 reverse transcriptase and exhibits an attractive resistance profile against a broad spectrum of NNRTI-resistant viruses (Bonneau et al., 2005) .
BILR 355 has a very short half life (2 to 5 h) and low exposure after oral administration to humans (Huang et al., 2008) . In vitro metabolism studies suggested that cytochrome P450 (CYP) 3A4 was playing a significant role in limiting systemic exposure to BILR 355 (ref. companion paper) . Ritonavir (RTV) is a potent inhibitor of CYP3A that has been used as a boosting agent to increase the exposure of a number of drugs, such as atazanavir and darunavir (Hull and Montaner, 2011) . After concomitant administration of BILR 355 with RTV, BILR 355 exposure improved dramatically with AUC increasing 16-to 30-fold (Huang et al., 2008) . However, an unexpected consequence of this boosting strategy was that a metabolite, BILR 516 ( Fig. 1) , which was not detected previously in humans given BILR 355 alone, emerged as a disproportionate human metabolite (DHM) with plasma levels exceeding those of parent at steady-state (Ref. companion paper).
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The appearance of BILR 516 as a DHM provided challenges in achieving adequate plasma exposure in preclinical species to cover the human systemic levels. It was therefore of interest to explore how this metabolite was formed. This paper delineates the metabolic pathways for the conversion of BILR 355 to the DHM, BILR 516, and discusses the importance of two individually atypical enzymes in drug development, which in combination provided a unique metabolic pathway. In addition, this paper clearly elucidates the complicated mechanisms of the metabolic switching of BILR 355 upon concomitant administration of the boosting agent, RTV.
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Materials and Methods
Chemicals, Reagents and Other Materials. BILR 355, BILR 402, and BILR 516 were synthesized at Boehringer Ingelheim Pharmaceuticals, Inc (Ridgefield, CT) (Fig. 1) .
BILR 483 (D 3 -BILR 355 with three deuterium on the methyl group) and nevirapine were also synthesized at Boehringer Ingelheim Pharmaceuticals, Inc. NADPH was purchased from Sigma-Aldrich (St. Louis, MO). All other reagents and solvents were of analytical grade or higher purity and were obtained from commercial suppliers. Pooled human liver microsomes (HLMs), human liver (HL) cytosol, and HL S9 were obtained from BD Biosciences (Woburn, MA). Individual lots of HLMs (ID # HL081696 and # HL082396B) were prepared in-house. All recombinant CYPs (produced in baculovirusinfected insect cells) and control insect cell microsomes were obtained from BD Biosciences. Cytosolic extract of Escherichia Coli expressing recombinant human aldehyde oxidase (AO) and control cytosolic extract of Escherichia Coli without recombinant human AO were purchased from Cypex Ltd (Dundee, Scotland, UK). All enzymes were stored at -80 °C until used.
In Vitro Incubations. Incubations were carried out in 0.05 M potassium phosphate buffer, pH 7.4. For incubations with rCYP, HLMs, and HL S9 using NADPH as the cofactor, substrates, inhibitors (when needed), and enzymes were pre-incubated in buffer for 5 minutes at 37 °C and each reaction was initiated with the addition of NADPH at a final concentration of 2.5 mM. For incubations with HL cytosol and S9 in the absence of NADPH, enzymes and inhibitors (when needed) were pre-incubated for 5 minutes at 37°C and each reaction was initiated with the addition of substrate. The final concentrations of enzymes varied and are specified in each study as described below.
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The final incubation volume was 0.5 mL or 1 mL and the final organic solvent concentration in each reaction did not exceed 1%. Reactions were carried out for 60 min and at the specified time points, a 50 µL aliquot was transferred to a glass filter plate assembly containing 100 µL of quench solution (0.1 µM nevirapine in acetonitrile or 0.2 µM nevirapine in 40% acetonitrile, 59.9% water and 0.1% acetic acid). The filter plate assembly was centrifuged at 1600 g for 10 min at 4°C. Filtrates from the centrifugation step were analyzed by LC-MS/MS (high performance liquid chromatography-tandem mass spectrometry). Each experiment was performed in duplicate. The general in vitro incubation conditions were applied to all assays described below unless specifically stated. In Vitro Gut Bacteria Incubation. Individual fecal samples from two healthy male volunteers were collected and transferred to an anaerobic chamber (Coy laboratory products, Inc., Grass Lake, MI). The Coy anaerobic chamber provides a strict anaerobic condition of 0-5 parts per million oxygen atmosphere through a hydrogen gas (5% in nitrogen gas) reacting with a palladium catalyst to remove oxygen. A heavy duty vacuum airlock is connected to the chamber, which allows sample transfer without changes to the internal atmosphere. Dulbecco's phosphate-buffered saline (DPBS) was stirred in the anaerobic chamber overnight to remove oxygen. The fecal samples were mixed with DPBS to obtain a concentration of 0.1 g/mL (weight of fecal sample/volume DMD #44362 of DPBS). The samples were then homogenized and centrifuged at 20 g for 5 min at 4 o C to remove debris. The supernatant was diluted to 0.05 g/mL. The samples were transferred to individual wells and pre-incubated for 5 min at 37 ºC. Reactions were initiated by the addition of BILR 355 at a final concentration of 100 µM to each sample.
Incubation of BILR
The incubations were performed in duplicate at 37 ºC. Reactions were terminated at 0, 2. 5, 5, 7.5, 10, 15, 20, 30, 40, 60, 90 , and 120 min and the formation of BILR 402 was measured by LC-MS/MS. All of the in vitro steps up to reaction termination were carried out under anaerobic condition.
Incubation of BILR 402 with Hepatic Enzymes. BILR 402, at a final concentration of 10 µM, was incubated with HL S9 or cytosol. Final protein concentration employed in this study was 1 mg/mL. The amount of BILR 516 generated from BILR 402 was measured at 10, 20, 30, and 60 min by LC-MS/MS.
Inhibition of the Biotransformation of BILR 402 to BILR 516 in HL S9 and
Cytosol by Enzyme-Selective Inhibitors. To investigate the role of cytosolic enzymes involved in the formation of BILR 516 from BILR 402, BILR 402 (5 µM) was incubated with HL S9 or cytosol at a final protein concentration of 0.5 mg/mL in the presence of various selective inhibitors. The selective chemical inhibitors used in this study were as follows: menadione 50 µM and hydralazine 50 µM for AO, allopurinol 50 µM for xanthine oxidase, disulfiram 50 µM for aldehyde dehydrogenase, and pyrazole 100 µM for alcohol dehydrogenase (Rochat et al., 1998) . Controls were performed in the absence of the inhibitors. The incubations were carried out for 60 min and the formation of BILR 516 was measured at 5, 10, 20, 30, and 60 min by LC-MS/MS. This article has not been copyedited and formatted. The final version may differ from this version. 0.061, 0.122, 0.244, 0.488, 0.977, 1.95, 3.91, 7.81, 15.6, 31.3, 62.5, 125 µM). The incubations were carried out for 10 min at a cytosolic protein concentration of with HL cytosol were calculated. The kinetic parameters were determined by non-linear regression analysis using Graph Pad Prism 5 (La Jolla, CA) and fit to a biphasic equation (Tracy, 2006) a value of 80.7 mg of cytosolic protein/g of liver (Houston and Galetin, 2008) , 1800 g of human liver weight, and average 70 kg of human body weight (Davies and Morris, 1993) .
To calculate the hepatic clearance, the well stirred model was applied and CL h1 (mL/min/kg) was calculated using the following equation (Pang and Rowland, 1977) : 
Results
The DHM BILR 516 is not Generated Directly from BILR 355. BILR 355 was incubated with HLMs, HL S9, or HL cytosol over 60 min at a concentration of 5 µM, which was close to the maximal plasma concentration of BILR 355 in humans (1500 ng/mL, ~ 3.40 µM) at steady state after oral administration of 150 mg BILR 355 and 100 mg RTV twice a day (Huang et al., 2009) . No formation of the DHM was observed, suggesting that the DHM is not formed directly from BILR 355. was not detected in S9 incubations without NADPH or in the cytosol incubations.
A role for AO in the formation of the DHM from the reduced metabolite was supported by studies using specific chemical inhibitors of major cytosolic enzymes, including menadione and hydralazine for AO, allopurinol for xanthine oxidase, disulfiram for aldehyde dehydrogenase, and pyrazole for alcohol dehydrogenase. The results are shown in Table 1 . In the presence of menadione or hydralazine, two specific inhibitors of AO, the formation of the DHM from the reduced metabolite was almost completely abolished. The inhibition effects by other chemical inhibitors were negligible, except that disulfram, a specific inhibitor of aldehyde dehydrogenase, inhibited the reaction more than 50%. However, it has been reported that disulfiram can also inhibit AO (Kitamura et al., 2001 ). In addition, aldehyde dehydrogenase is known to oxidize only aldehyde to acid, while aldehyde oxidase can catalyze nucleophilic oxidation at an electro-deficient carbon atom in N-heterocycles (e.g. quinoline) (Beedham et al., 2003) .
This article has not been copyedited and formatted. The final version may differ from this version. Furthermore, the reduced metabolite was incubated with recombinant human AO and the formation of the DHM was clearly observed (Fig. 5) . The DHM was not generated in the control cytosol without recombinant human AO.
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 6A and indicated that the kinetics followed a biphasic model. The apparent K m1 and V max1 values were obtained based on the biphasic model (Fig. 6B) . The intrinsic clearance of the high-affinity-low-capacity site, CL int1, in vitro , was calculated to be 437 µL/min/mg of cytosolic protein based on V max1 /K m1 . Subsequently, CL int1, in vivo was estimated as 907 mL/min/kg and CL h1 was calculated as 20.2 mL/min/kg.
Kinetic Analysis of the Metabolism of the Reduced Metabolite BILR 402 by
HLMs. Two lots of pre-characterized HLMs (HL081696 and HL082396B) were . Tranylcypromine, at a concentration of 100 µM, inhibited about 30% of the overall metabolism of the reduced metabolite, but had no effect on the formation of BILR 355.
Tranylcypromine is an inhibitor of CYP2C19 and CYP2A6 (Dierks et al., 2001 ).
However, another more potent CYP2C19 inhibitor, ticlopidine, did not inhibit the metabolism of the reduced metabolite and as shown above, neither recombinant Since the DHM had not been previously observed in humans administered BILR 355 alone, it was important to elucidate the metabolic pathway and identify enzymes responsible for the conversion of BILR 355 to the DHM. In this paper, two atypical enzymatic processes were identified, which in combination, provided a unique metabolic pathway. In addition, the metabolic switching of BILR 355 with concomitant administration of RTV was also elucidated.
We first explored potential metabolic mechanisms for the biotransformation of BILR 355 to the DHM. This biotransformation involves reduction of the N-oxide and oxidation on the carbon next to the N-oxide. The likelihood of this biotransformation as a single step reaction is low, which was confirmed by the in vitro incubations of BILR 355 with HLMs, HL S9, and HL cytosol, where no formation of the DHM was observed.
Our hypothesis was that this biotransformation is a two-step process with the reduced metabolite, BILR 402, as the intermediate. The first step would be reduction of BILR 355
to BILR 402. Reduction of N-oxide has been shown to occur presystemically or by hepatic enzymes (Sousa et al., 2008; Guengerich, 2001; Kitamura and Tatsumi, 1984a; Kitamura and Tatsumi, 1984b) . The second step is the oxidation of BILR 402 at the This article has not been copyedited and formatted. The final version may differ from this version. finding is consistent with observations from the 14 C ADME animal studies for BILR 355, which indicated that unchanged BILR 355 was present in only trace amounts in feces of mice, rats, and dogs (0-3.3% of the total radioactivity) and the majority of fecal radioactivity could be accounted for by the reduced metabolite and its down-stream metabolites (72.5%-90.4% of the total radioactivity) (Boehringer Ingelheim Pharmaceuticals, Inc., data on file).
The second step is mediated by AO as confirmed with selective chemical inhibitors (Table 1 ), incorporation of oxygen from H 2 O (Fig. 4) , and metabolism by recombinant AO (Fig. 5) . In addition, the activity was found in the cytosolic subcellular fraction (Over 80% conversion from the reduced metabolite to the DHM by 60 min) and did not require NADPH (Fig. 3A) .
The biotransformation of the reduced metabolite to form the DHM followed biphasic kinetics with a low K m1 value of 0.772 µM (Fig. 6 ). The turnover of the reduced metabolite to the DHM is predicted to be high, with a calculated in vivo hepatic clearance of 20.2 mL/min/kg which approximates hepatic blood flow in humans (20.7 mL/min/kg), This article has not been copyedited and formatted. The final version may differ from this version. (Zientek et al., 2010) .
With the combination of two highly efficient metabolic reactions (BILR 355 forms the reduced metabolite which is then further metabolized to the DHM) and the long in vivo half-life of the DHM (54.5 h, Ref. companion paper), it is not surprising to see the high exposure of the DHM at steady state in humans.
The reduced metabolite, BILR 402, is the intermediate of the biotransformation from BILR 355 to the DHM. As such, the metabolism of the reduced metabolite was studied.
The reduced metabolite was extensively metabolized by CYPs to other products, as demonstrated by high hepatic clearance (> 20 mL/min/kg) of the reduced metabolite (Table 2) . When the reduced metabolite was incubated with HL S9, there was substantially less of the DHM formed in the presence of NADPH compared to the absence (Fig. 3B ). This could be attributable to extensive metabolism of the reduced metabolite by CYPs in the presence of NADPH, thus minimal substrate was available for AO metabolism at later time points (i.e. beyond 10 min). In addition, it is also possible that the DHM can be further metabolized by CYPs, which could offset the formation of the DHM by AO and result in nearly zero net change of the DHM level after 10 min. The reduced metabolite can also be oxidized back to the parent BILR 355 by CYPs as shown in HLM (11% for HL081696 and 22% for HL082396B of the overall intrinsic clearance of the reduced metabolite; Table 2 ). CYP3A4 was identified as the major CYP isoform responsible for the metabolism of the reduced metabolite and specifically the formation of BILR 355 based on studies using recombinant CYP isoforms and isoforms-selective inhibitors. Although not tested in these studies, CYP3A5 may also be involved in the There are 100 trillion microbes resident in a normal human intestine with a higher density in the lower GI tract (Ley et al., 2006) . Due to the complexity of drug development, more and more drugs are developed with low solubility, low permeability, or administered with extended release formulations. As such, these drugs will be more likely to reach the lower GI tract, presenting themselves to the host gut bacteria (Sousa et al., 2008) . The possible involvement of gut bacteria in the metabolism of drugs needs to be seriously considered.
In addition, AO-mediated metabolism is drawing more and more attention in drug development. Two key areas of concern are the potential for low oral bioavailability of development compounds in humans, resulting from high turnover by AO, and also the marked species differences in AO activity leading to gross species differences in exposure of metabolites formed by AO (Pryde et al., 2010) . Generally, high AO activity is observed in human and monkey, followed by hamster, rabbit, guinea pig, rat, and mouse, and AO is deficient in dog (Kitamura et al., 2006; Beedham et al., 1995; Kitamura et al., 2001; Beedham et al., 1987) . Since AO activity is generally low or deficient in the standard Toxicology species, a metabolite generated by AO that is major in humans (>10% of the total drug related materials), has a higher chance of being a DHM. BILR 355 metabolism provides a clear example of this issue.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
